EUVIMEDDescoperă EUVIMED
Beobachtungsstudie

Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma

Angeline A Truong iD, Rex H Lee, Xin Wu, Alain P Algazi, Hyunseok Kang, Ivan H El-Sayed, Jonathan R George, Chase M Heaton, William R Ryan, Yena Jeon, Mi-Ok Kim, Patrick K Ha and 1 more

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.1088 ↗

At a glance

Beobachtungsstudie in Otolaryngology–Head and Neck Surgery, 2025. Written by Angeline A Truong and 12 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Neutrophils, Antibodies, Monoclonal, Humanized, Mouth Neoplasms, Antineoplastic Agents, Immunological. Cited 5 times so far (Crossref); 32 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Objective

To determine the relationship between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) oral cavity cancer on pembrolizumab. Study Design This study was a retrospective, observational study performed at a tertiary care academic center.

Setting

Participants included patients with oral cavity squamous cell carcinoma (OCSCC) who began pembrolizumab treatment at the University of California, San Francisco between May 2016 and May 2022.

Methods

The primary outcome was a 6‐month PFS. The secondary outcome was a 2‐year OS. NLR was treated as a continuous variable. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors.

Results

Fifty‐two patients with OCSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. The median pretreatment NLR was 5.7 (interquartile range: 3.6‐7.6). Twenty‐seven (55%) patients received pembrolizumab alone. Of those receiving treatment for R/M prior to ICI, 9 (18%) received salvage surgery and adjuvant therapy, 2 (4%) received chemotherapy alone, 1 (2%) received chemoradiation, and 10 (20%) received salvage surgery. Nineteen (36.5%) patients had distant metastases at the start of ICI. Six‐month PFS was 46%. Two‐year OS was 44%. NLR was independently associated with 6‐month PFS [hazard ratio, HR: 1.05 (95% confidence interval, CI: 1.01‐1.11), P = .028] and 2‐year OS [HR: 1.12 (95% CI: 1.05‐1.20), P < .001].

Conclusion

Higher pretreatment NLR was associated with poorer 6‐month PFS and 2‐year OS in OCSCC patients treated with pembrolizumab.

Subjects

MeSH terms (MEDLINE)

NeutrophilsAntibodies, Monoclonal, HumanizedMouth NeoplasmsAntineoplastic Agents, ImmunologicalCarcinoma, Squamous CellLymphocytesHumansMaleRetrospective StudiesFemaleMiddle AgedAgedTreatment OutcomeSurvival Rate

Author keywords

NLRhead and neck cancerimmune checkpoint inhibitorneutrophil‐to‐lymphocyte ratiooral cavity cancerpembrolizumab

Substances

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

ORCID profiles: Angeline A Truong

Cite

APA

Truong, A. A., Lee, R. H., Wu, X., Algazi, A. P., Kang, H., El-Sayed, I. H., George, J. R., Heaton, C. M., Ryan, W. R., Jeon, Y., Kim, M. O., Ha, P. K., & Wai, K. C. (2025). Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1088

Vancouver

Truong AA, Lee RH, Wu X, Algazi AP, Kang H, El-Sayed IH, et al. Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1088

BibTeX
@article{Truong2025,
  author = {Truong, Angeline A and Lee, Rex H and Wu, Xin and Algazi, Alain P and Kang, Hyunseok and El-Sayed, Ivan H and George, Jonathan R and Heaton, Chase M and Ryan, William R and Jeon, Yena and Kim, Mi-Ok and Ha, Patrick K and Wai, Katherine C},
  title = {Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.1088}
}
Start for free →